Cardiovascular risk-benefit profile of sibutramine

American Journal of Cardiovascular Drugs

Volumn 10, Issue 5, 2010, Pages 321-334

  Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Benefit risk assessment; Cardiovascular disorders, drug induced; Obesity, treatment; Sibutramine, adverse reactions; Sibutramine, therapeutic use

Indexed keywords

ADIPONECTIN; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESMOLOL; FATTY ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; RESISTIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ABDOMINAL OBESITY; ADRENERGIC SYSTEM; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; AUTONOMIC NERVOUS SYSTEM; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET; DIZZINESS; DRUG ABUSE; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG MARKETING; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; EXERCISE; FATTY ACID BLOOD LEVEL; GLUCOSE METABOLISM; HEADACHE; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; INSOMNIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRINSIC SYMPATHOMIMETIC ACTIVITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; QT PROLONGATION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE; SWEATING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA;

APPETITE DEPRESSANTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CYCLOBUTANES; GLUCOSE; HEART RATE; HUMANS; INSULIN RESISTANCE; RISK FACTORS;

EID: 77957292772     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11584800-000000000-00000     Document Type: Review

References (114)

1. Hofbauer KG, Nicholson JR, Boss O. The obesity epidemic: current and future pharmacological treatments. Ann Rev Pharmacol Toxicol 2007;47:565-92 (Pubitemid 46272139)
2. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952-67 (Pubitemid 39473623)
3. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918 (Pubitemid 43754312)
4. Després JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008;28:1039-49
5. Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003;63:1165-84
6. Reisin E, Jack AV. Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches. Med Clin North Am 2009;93:733-51
7. Mathieu P, Lemieux I, Després JP. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther 2010;87:407-16
8. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-80 (Pubitemid 46028447)
9. Zalesin KC, Franklin BA, Miller WM, et al. Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am 2008;37:663-84
10. Douketis JD, Sharma AM. Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction. Semin Vasc Med 2005;5:25-33
11. Bodary PF, Iglay HB, Eitzman DT. Strategies to reduce vascular risk associated with obesity. Curr Vasc Pharmacol 2007;5:249-58
12. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53:1925-32
13. Lloret-Linares C, Greenfield JR, Czernichow S. Effect of weight-reducing agents on glycaemic parameters and progression to type 2 diabetes: a review. Diabet Med 2008;25:1142-50
14. Choussein S, Makri AA, Frangos CC, et al. Effect of antiobesity medicationsin patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11:641-64
15. Buse JB, Ginsberg HN, Bakris GL, et al., American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162-72 (Pubitemid 46052519)
16. Scheen AJ. Integrated approach to treatment and prevention. In: Hofbauer KG, Keller U, Boss O, editors. Pharmacotherapy of obesity: options and alternatives. Boca Raton (FL): CRC Press, 2004:449-63
17. Scheen AJ. The future of obesity: new drugs versus lifestyle interventions. Expert Opin Investig Drugs 2008;17:263-7
18. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005;65:1391-418 (Pubitemid 41043893)
19. Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology 2007;132:2239-52
20. Li M, Cheung BM. Pharmacotherapy for obesity. Br J Clin Pharmacol 2009;68:804-10
21. Idelevich E, Kirch W, Schindler C. Current pharmacotherapeutic concepts for the treatment of obesity in adults. Ther Adv Cardiovasc Dis 2009;3:75-90
22. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 2005;143:380-5 (Pubitemid 41266610)
23. Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol 2009;68:861-74
24. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products used in weight control, 1 Jun. 2006 [online]. Available from URL: http://www.ema.europa.eu/ pdfs/human/ewp/028196enpdf [Accessed 2010 Jul. 18]
25. Scheen AJ, Lefèbvre PJ. Pharmacological treatment of obesity: present status. Int J Obes 1999;23 Suppl. 1:47-53 (Pubitemid 29101376)
26. Collins P, Williams G. Drug treatment of obesity: from past failures to future successes? Br J Clin Pharmacol 2001;51:13-25 (Pubitemid 32118816)
27. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf 2005;4:1083-95
28. Robinson JR, Niswender KD. What are the risks and the benefits of current and emerging weight-loss medications? Curr Diab Rep 2009;9:368-75
29. McNeely W, Goa KL. Sibutramine: a review of its contribution in the management of obesity. Drugs 1998;56:1093-124 (Pubitemid 29010230)
30. Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 2000;1:127-39
31. Sharma B, Henderson DC. Sibutramine: current statusasan anti-obesity drug and its future perspectives. Expert Opin Pharmacother 2008;9:2161-73
32. Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag 2009;5:441-52
33. Luque CA, Rey JA. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 2002;440:119-28 (Pubitemid 34458019)
34. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994-1003 (Pubitemid 38581520)
35. Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004;164:1395-404 (Pubitemid 38937850)
36. Scheen AJ, Ernest Ph. Antiobesity treatment in type 2 diabetes: results of clinical trials with orlistat and sibutramine. Diabetes Metab 2002;28:437-45 (Pubitemid 36077145)
37. Neovius M, Johansson K, Rössner S. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and metaanalysis. Obes Rev 2008;9:420-7
38. James WPT, Astrup A, Fier N et al., for the STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000;356:2119-25 (Pubitemid 32047947)
39. Scheen AJ, Paquot N. Pharmacological treatment of obesity, food intake, and reversal of metabolic disorders. Curr Nutr Food Sci 2007;3:123-33 (Pubitemid 46773888)
40. Vettor R, Serra R, Fabris R, et al. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 2005;28:942-9 (Pubitemid 40434504)
41. Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003;26:1027-48 (Pubitemid 37452644)
42. Ioannides-Demos LL, Proietto J, Tonkin AM, et al. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006;29:277-302
43. Guven A, Koksal N, Cetinkaya A, et al. Effects of the sibutramine therapy on pulmonary artery pressure in obese patients. Diabetes Obes Metab 2004;6:50-5 (Pubitemid 38159729)
44. Bach DS, Rissanen AM, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999;7:363-9
45. Pereira JL, López-Pardo F, Parejo J, et al. Study of heart valve function in obese patients treated with sibutramine. Med Clin (Barc) 2002;118:57-9 (Pubitemid 34814789)
46. Narkiewicz K. Sibutramine and its cardiovascular profile. Int J Obes Relat Metab Disord 2002;26 Suppl. 4: S38-41 (Pubitemid 36071971)
47. de Simone G, Romano C, De Caprio C, et al. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. Nutr Metab Cardiovasc Dis 2005;15:24-30 (Pubitemid 40546030)
48. de Simone G, D'Addeo G. Sibutramine: balancing weight loss benefit and possible cardiovascular risk. Nutr Metab Cardiovasc Dis 2008;18:337-41
49. Chaput JP, Berube-Parent S, Tremblay A. Obesity and cardiovascular physiology: impact of some pharmacological agents. Curr Vasc Pharmacol 2005;3:185-93 (Pubitemid 40601587)
50. Kim SH, Lee YM, Jee SH, et al. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003;11:1116-23 (Pubitemid 41151589)
51. Filippatos TD, Kiotsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005;21:457-68
52. Mannucci E, Dicembrini I, Rotella F, et al. Orlistat and sibutramine beyond weight loss. Nutr Metab Cardiovasc Dis 2008;18:342-8 (Pubitemid 351749802)
53. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-9 (Pubitemid 350273303)
54. Faria AN, Ribeiro Filho FF, Kohlmann NE, et al. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes Obes Metab 2005;7:246-53
55. Valsamakis G, McTernan PG, Chetty R, et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004;53:430-4 (Pubitemid 38419183)
56. Jung SH, Park HS, Kim KS, et al. Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. Nutr Biochem 2008;19:371-5
57. Bray GA. Sibutramine and blood pressure: a therapeutic dilemma. J Hum Hypertens 2002;16:1-3
58. Haddock CK, Poston WS, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002;26:262-73
59. Horvath K, Jeitler K, Siering U, et al. Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Arch Intern Med 2008;168:571-80 (Pubitemid 351468391)
60. Johansson K, Sundstrom J, Neovius K, et al. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obes Rev 2009 Dec. 15. Epub ahead of print
61. Czernichow S, Lee CM, Barzi F, et al. Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials. Obes Rev 2010;11:150-8
62. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev 2008;9:378-87 (Pubitemid 351842191)
63. Scholze J, Grimm E, Herrmann D, et al. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007;115:1991-8 (Pubitemid 46625949)
64. Cook S, Togni M, Schaub MC, et al. High heart rate: a cardiovascular risk factor? Eur Heart J 2006;27:2387-93 (Pubitemid 44522142)
65. Haynes WG, Egri Z. Sibutramine and the sympathetic nervous system in obese humans. Clin Auton Res 2005;15:189-92 (Pubitemid 40909706)
66. Birkenfeld AL, Schroeder C, Boschmann M, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002;106:2459-65 (Pubitemid 35278802)
67. Birkenfeld AL, Schroeder C, Pischon T, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients: sibutramine and blood pressure. Clin Auton Res 2005;15:200-6 (Pubitemid 40909708)
68. Heusser K, Tank J, Diedrich A, et al. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 2006;79:500-8
69. Heusser K, Engeli S, Tank J, et al. Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab 2007;92:1560-3 (Pubitemid 46556440)
70. Hirsch J, Mackintosh RM, Aronne LJ. The effects of drugs used to treat obesity on the autonomic nervous system. Obes Res 2000;8:227-33
71. Quilliot D, Bohme P, Zannad F, et al. Sympathetic-leptin relationship in obesity: effect of weight loss. Metabolism 2008;57:555-62 (Pubitemid 351320605)
72. Duivenvoorden R, de Groot E, Stroes ES, et al. Surrogate markers in clinical trials: challenges and opportunities. Atherosclerosis 2009;206:8-16
73. Frick M, Weidinger F. Endothelial function: a surrogate endpoint in cardiovascular studies? Curr Pharm Des 2007;13:1741-50 (Pubitemid 46979712)
74. Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003;16:895-9 (Pubitemid 37315486)
75. Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002;144:508-15
76. Wirth A, Scholze J, Sharma AM, et al. Reduced left ventricular mass after treatment of obese patients with sibutramine: an echocardiographic multicentre study. Diabetes Obes Metab 2006;8:674-81 (Pubitemid 44515565)
77. Shechter M, Beigel R, Freimark D, et al. Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. Am J Cardiol 2006;97:1650-3 (Pubitemid 43737034)
78. de Groot E, van Leuven SI, Duivenvoorden R, et al. Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis. Nat Clin Pract Cardiovasc Med 2008;5:280-8 (Pubitemid 351593910)
79. Bosello O, Carruba MO, Ferrannini E, et al. Sibutramine lost and found. Eat Weight Disord 2002;7:161-7
80. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 2002;166:1307-8 (Pubitemid 34533957)
81. Johansson K, Neovius K, DeSantis SM, et al. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a metaanalysis. Obes Rev 2009;10:564-75
82. Patel MR, Donahue M, Wilson PW, et al. Clinical trial issues in weight-loss therapy. Am Heart J 2006;151:633-42 (Pubitemid 43290254)
83. Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity (Silver Spring) 2007;15:2712-22
84. Gaciong Z, Placha G. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. J Hum Hypertension 2005;19:737-43 (Pubitemid 43118098)
85. Seebeck J, Wulf F, Sachs B. Label-inconsistent use of sibutramine in spontaneous adverse drug reaction reports in Germany. Int J Clin Pharmacol Ther 2008;46:375-81 (Pubitemid 352005930)
86. Dahlin A, Beermann B. Incorrect use of orlistat and sibutramine in clinical practice. Eur J Clin Pharmacol 2007;63:205-9 (Pubitemid 46147063)
87. Harrison-Woolrych M, Ashton J, Herbison P. Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine: a prospective cohort study. Drug Safety 2010;33:605-13
88. Scheen AJ. Controversy about the cardiovascular safety of sibutramine. Drug Safety 2010;33:615-8
89. Harrison-Woolrych M, Clark DW, Hill GR, et al. QT interval prolongation associated with sibutramine treatment. Br J Clin Pharmacol 2006;61:464-9
90. Yalcin AA, Yavuz B, Ertugrul DT, et al. Elevation of QT dispersion after obesity drug sibutramine. J Cardiovasc Med (Hagerstown). 2010 Jul. 27. Epub ahead of print
91. Ernest D, Gershenzon A, Corallo CE, et al. Sibutramine-associated QT interval prolongation and cardiac arrest. Ann Pharmacother 2008;42:1514-7
92. Kim KS, Kim EJ, Lee HA, et al. Effect of sibutramine HCl on cardiac hERG K+ channel. Mol Cell Biochem 2009;320:125-31
93. Azarisman SM, Magdi YA, Noorfaizan S, et al. Myocardial infarction induced by appetite suppressants in Malaysia. N Engl J Med 2007;357:1873-4 (Pubitemid 350044825)
94. Yim KM, Ng HW, Chan CK, et al. Sibutramine-induced acute myocardial infarction in a young lady. Clin Toxicol (Phila) 2008;46:877-9
95. Eroglu E, Gemici G, Bayrak F, et al. Acute myocardial infarction in a 24 yearold man possibly associated with sibutramine use. Int J Cardiol 2009;137: e43-5
96. Gómez-Barrado JJ, Turégano S, Garcipérez de Vargas FJ, et al. Acute coronary syndrome in a young woman treated with sibutramine [letter]. Rev Esp Cardiol 2010;63:242-3
97. Sayin T, Güldal M. Sibutramine: possible cause of a reversible cardiomyopathy. Int J Cardiol 2005;99:481-2 (Pubitemid 40364006)
98. Kim KA, Song WK, Park JY. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin Pharmacol Ther 2009;86:511-8
99. Chung JY, Jang SB, Lee YJ, et al. Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J Clin Pharmacol 2010 Mar. 29. Epub ahead of print
100. Tomalik-Scharte D, Lazar A, Fuhr U, et al. The clinical roleofgenetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 2008;8:4-15
101. Minns AB, Ebrahimi S, Te L, et al. Aretrospective review of California poison control system data of sibutramine exposures. Clin Toxicol (Phila) 2009;47:814-7
102. James WPT. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J 2005;7(Suppl. L): L44-8
103. Torp-Pedersen C, Caterson I, Coutinho W, et al., SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007;28:2915-23 (Pubitemid 350233016)
104. Sharma AM, Caterson ID, Coutinho W, et al., SCOUT Investigators. Blood pressure changes associated with sibutramine and weight management: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes Obes Metab 2009;11:239-50
105. Van Gaal LF, Caterson ID, Coutinho W, et al., SCOUT Investigators. Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. Diabetes Obes Metab 2010;12:26-34
106. Weeke P, Andersson C, Fosbøl EL, et al. The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus: an analysis from the SCOUT lead-in period. BMC Endocr Disord 2010;10:3 doi:10.1186/1472-6823-10-3
107. Maggioni AP, Caterson I, Coutinho W, et al., SCOUT Investigators. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. J Cardiovasc Pharmacol 2008;52:393-402
108. Caterson I, Coutinho W, Finer N, et al., for the SCOUT Investigators. Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring) 2010;18:987-94
109. Andersson C, Weeke P, Brendorp B, et al. Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. Nutr Metab 2009;6:42
110. von Haehling S, Lainscak M, Anker SD. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon? Eur Heart J 2007;28:2830-1 (Pubitemid 350233044)
111. James WPT, Caterson ID, Coutinho W, et al., for the SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-17
112. Williams G. Withdrawal of sibutramine in Europe. BMJ 2010 Feb. 9; 340: c824. doi: 10.1136/bmj.c824
113. European Medicines Agency. European Medicines Agency recommends suspension of marketing autorisation for sibutramine [online]. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2 [Accessed 2010 Jul. 18]
114. US Food and Drug Administration. Meridia (sibutramine hydrochloride): follow-up to an early communication about an ongoing safety review [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/Safety Information/SafetyAlertsforHumanMedicalProducts/ucm198221.htm [Accessed 2010 Jul. 18]